Table 1 Information of recombinant PRVs
From: Design of live-attenuated animal vaccines based on pseudorabies virus platform
Foreign Genes | Insertion sites (gene) | Neutralizing Antibodies | Dose for immunization | Host | Route of vaccination | PRV vector (strain) | Challenged virus (strain, dose) | Protection efficiency and/or clinical outcome | Reference |
|---|---|---|---|---|---|---|---|---|---|
PCV2 ORF1-ORF2 | Between gI and gE | Yes | 105 TCID50 (mice/pig) | Mice & Pig | Footpad | PRV Ea | NA | NA | |
PCV2 ORF2 and IL-18 | gG | Yes | 107 TCID50 | Mice | Subcutaneous | PRV HB98 | PCV2 (HN strain, 5 × 105 TCID50) | Reduced viral load in animals | (Zheng et al. 2015) |
PCV2b Cap, CSFV E2, and Erns-GM-CSF | TK, gG and gE | Yes | 1.2 × 108 PFU | Pig | Intranasal& Subcutaneous | PRV Becker | PCV2 (PCV2b no. 40895, 2.275 × 104 PFU) | Better protection than Zoetis Fostera Gold PCV commercial vaccine | (Pavulraj et al. 2022) |
PPV VP2 | gI | Yes | 5 × 105 TCID50 | Pig | Intramuscular | PRV Fa | PPV (SC1, 1 × 106.5 TCID50) | 96% protection (n = 28) | (Chen et al. 2011) |
PPV VP2 and IL-6 | gG | Yes | 105 TCID50 | Mice | Intramuscular | PRV HB98 | PPV (HN strain, 106 TCID50) | 90% protection (n = 10) | (Zheng et al. 2020) |
JEV NS1 | gG | Yes | 105 PFU (mice/pig) | Mice & Pig | Intramuscular | PRV Ea | JEV (SA14–14-2, 105 PFU) | Developed good humoral and cellular immune response against JEV | (Xu et al. 2004) |
JEV PrM-E | Between gI and gE | Yes | 106 TCID50 | Mice | Intramuscular | PRV Ea | JEV (SX09S-01; 107 PFU) | 80% (n = 10) | (Qian et al. 2015) |
PRRSV GP5 and M | TK | No | 107 PFU | Pig | Intramuscular & Intranasal | PRV Bartha-K61 | PRRSV (CH-1a 106.5 TCID50) | Mild lesions in the lungs and kidneys | (Qiu et al. 2005) |
PRRSV GP5m and M | Between gI and gE | Yes | 105 PFU (mice)/ 106 PFU (pig) | Mice & Pig | Intramuscular | PRV Ea | PRRSV (YA1, 5 × 105 TCID50) | No clinical signs | (Jiang et al. 2007) |
PRRSV GP5 and M | TK, gI and gE | Yes | 106 TCID50 | Mice | intramuscular | PRV XJ | NA | NA | (Zhao et al. 2022) |
FMDV P12A and 3C | Between gI and gE | Yes | 106 TCID50 | Pig | Intramuscular | PRV Ea | FMDV (O/ES/2001, 106 TCID50) | 60% (n = 5) | (Zhang et al. 2011) |
SIV HA (H3N2) | TK | Yes | 105 PFU | Mice | Intranasal | PRV Bartha-K61 | SwHLJ74 (H3N2 strain, 105 TCID50) | Mild pathological lesions limited in lung | (Tian et al. 2006) |
SIV HA (H1N1) | gG | Yes | 2 × 107 PFU | Pig | Intranasal | PRV Bartha-K61 | SoIV (A/California/7/09 strain, 2 × 106 TCID50) | The vaccinated animals were protected from clinical signs | (Klingbeil et al. 2014) |
CSFV E2 | Between gI and gE | Yes | 106 TCID50 | Pig | Intramuscular | PRV TJ | CSFV (Shimen, 106TCID50) | 100% (n = 5) | (Lei et al. 2016) |
Brucella BP26 | Between gI and gE | Yes | 104 TCID50 | Mice | Intramuscular | PRV Ea | NA | NA | (Yao et al. 2015) |
Toxoplasma gondii SAG1 | Between PK and gE | Yes | 6 × 105 PFU | Mice | Intramuscular | PRV Bartha-K61 | 50 virulent T. gondii trophozoites | 60% (n = 15) | (Liu et al. 2008) |
Toxoplasma gondii SAG1 and MIC3 | gG | Yes | 106 TCID50 | Mice | Intramuscular | PRV Ea | 100 virulent T. gondii tachyzoites | 66.7% protection (n = 6) | (Nie et al. 2011) |
Schistosoma japonicum Sj26GST and SjFABP | Between PK and gG | Yes | 6 × 105 PFU (mice)/ 1.2 × 106 PFU (sheep) | Mice & Sheep | Intramuscular | PRV Bartha-K61 | 40 ± 2 (mice) and 400 ± 2 (sheep) S. japonicum | Worm reduction 39.3% in mice and 48.5% in sheep | (Wei et al. 2010) |